Clinical Research on the Comparative Effectiveness and Safety of JHG002 Therapy for Chronic Low Back Pain: A Multicenter Randomized Controlled Trial
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Device, Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
A multicenter randomized controlled trial
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Maximum Age: 70
Healthy Volunteers: f
View:
• Adults aged 19 to 69 years at the time of signing the informed consent.
• Individuals who have experienced low back pain for ≥6 months, presenting with either continuous or intermittent symptoms.
• Participants with a Numeric Rating Scale (NRS) score ≥ 5 for low back pain at screening.
• Individuals who fully understand the clinical trial procedures and voluntarily agree to participate by providing written informed consent.
Locations
Other Locations
Republic of Korea
Bucheon Jaseng Hospital of Korean Medicine
RECRUITING
Bucheon-si
Dongguk University Bundang Oriental Hospital
RECRUITING
Seongnam
Jaseng Hospital of Korean Medicine
RECRUITING
Seoul
Kyung Hee University Korean Medicine Hospital at Gangdong
RECRUITING
Seoul
Contact Information
Primary
In-Hyuk Ha, Dr
hanihata@gmail.com
+82-1577-0007
Time Frame
Start Date: 2025-12-17
Estimated Completion Date: 2029-11-28
Participants
Target number of participants: 96
Treatments
Experimental: Hominis placental pharmacopuncture
Participants in the experimental group will receive JHG002 pharmacopuncture twice weekly for 5 weeks (total 10 sessions). JHG002 (0.05-0.1 mL per point) will be administered to 8-10 acupuncture points commonly used for chronic low back pain, including BL23, BL24, BL25, GV3, and GV4, with optional GB30 based on symptoms.
Active_comparator: Physical Therapy Group
Participants in the control group will receive standardized transcutaneous electrical nerve stimulation (TENS) therapy twice weekly for 5 weeks (total 10 sessions). Each session will last 15 minutes and will be administered using a unified protocol across all participating sites to target the lumbar region.
Related Therapeutic Areas
Sponsors
Leads: Jaseng Medical Foundation